MEDVi vs Ivim Health (2026): Cost, Cancellation, Verdict
By the Weight Loss Provider Guide editorial team — an independent comparison resource for GLP-1 telehealth providers.
If you're trying to choose between MEDVi vs Ivim Health for compounded semaglutide or tirzepatide, here's the bottom line. MEDVi is the lower-friction starting path — entry pricing of $179 for compounded GLP-1 injections, no separate membership fee on the compounded program, and month-to-month billing that you can cancel through your account dashboard with at least 72 hours' notice before your next billing date. Ivim Health is the cheaper long-haul play — about $150/month total on a 12-month compounded semaglutide plan ($75 medication + $74.99 program fee). Over 12 months of compounded semaglutide, the gap between them is roughly $1,743. Over 6 months, it's about $700.
There's one more thing to know upfront: both companies received FDA warning letters dated February 20, 2026 — the same day, same enforcement wave, 30 telehealth companies total. Both letters cited misbranding in marketing language, not medication safety. Both companies remain operational. We disclose this now because hiding it would lose us the right to be trusted on anything else.
At-a-glance: MEDVi vs Ivim Health snapshot
Verified April 28, 2026. Verify current pricing on each provider's site before enrolling.
| Decision factor | MEDVi | Ivim Health |
|---|---|---|
| Entry price (compounded GLP-1 injection) | $179 | $75/mo medication + $74.99 program fee = $149.99/mo (12-mo plan) |
| Standard refill / ongoing (compounded sema) | $299/mo (verify at checkout) | $149.99/mo total on 12-mo plan; $174.99/mo total on 6-mo plan |
| Compounded GLP-1 tablets (oral) | ✅ Yes — starting at $249 | ❌ Injection only |
| Brand-name FDA-approved options | Wegovy Pill, Wegovy Injection, Zepbound Injection — $99 membership + medication cost | Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda with prior-auth support |
| Plan structure | Month-to-month, plus 3, 6, 12-mo options | 1, 2, 4, 6, or 12-month prepay only |
| Mid-plan cancellation | Cancel anytime with 72-hour pre-billing notice; no admin fees on month-to-month | Admin fees apply on prepaid plans ($50–$100 per remaining segment) |
| Money-back terms | "MEDVi Guarantee" advertised; full refund for medical disqualification — verify current results-based terms at checkout | No published results-based guarantee |
| Trustpilot rating | 4.4 / 5 (~12,500+ reviews; 78% 5-star, 11% 1-star) | 4.9 / 5 (~36,700+ reviews; 94% 5-star, 2% 1-star) |
| BBB | F rating, not accredited, 368 complaints | A+ rating, accredited since Feb 2023 |
| Feb 20, 2026 FDA warning letter | Yes — Letter #721455 (misbranding, marketing/labeling) | Yes — Letter #721816 (misbranding, marketing/labeling) |
| Best for | Lower-commitment starters, tablet preference, brand-name self-pay, want flexibility | Long-term committed shoppers wanting structure and brand-name with insurance |
What we actually verified for this comparison
- ✓Both providers’ current pricing pages — MEDVi’s GLP-1 program page and Ivim’s pricing page, accessed April 28, 2026
- ✓Both providers’ Terms of Service and refund/cancellation policies — including Ivim’s Subscription Agreement and MEDVi’s published Refund Policy
- ✓Both FDA warning letters — pulled directly from FDA.gov: Letter #721455 to MEDVi, LLC, and Letter #721816 to Ivim Services LLC, both dated February 20, 2026
- ✓Both BBB profiles — including current accreditation status, ratings, and complaint volume
- ✓Trustpilot rating distributions — both providers’ live profiles, including the percentage of 5-star and 1-star reviews
- ✓MEDVi's currently disclosed pharmacy partners — Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding (per MEDVi's published Terms)
- ✓FDA's general guidance on compounded GLP-1 medications, drug-shortage status, and consumer warnings
What we did not do: enroll in either program ourselves. We don't claim first-person verification of fulfillment timelines or shipping speed.
How much do MEDVi and Ivim Health actually cost — past the first month?
The short answer: Ivim Health is meaningfully cheaper if you commit to a 6 or 12-month plan. MEDVi is cleaner if you want flexibility and don't want to prepay. For a buyer who actually completes 6 months on compounded semaglutide, the difference is about $700. Over 12 months, it's about $1,743. If you quit at month 2, MEDVi was probably the right call. If you stay the year, Ivim was.
The real semaglutide math
MEDVi's $179
This is the entry price for compounded GLP-1 injections on MEDVi's GLP-1 program. The standard refill rate listed in independent reviews is $299, though MEDVi's main page primarily highlights the $179 entry. Whether you stay closer to $179 longer-term depends on which offer path you signed up through — verify the refill price during intake.
Ivim's $75 (not the real number)
This is the medication-only price on Ivim's 12-month compounded semaglutide plan. It does not include Ivim's mandatory $74.99/month program fee, which Ivim collects every month after your first month. Your real monthly cost on the 12-month plan is $149.99, not $75. On the 6-month plan, the medication price climbs to $100/month, so your real monthly is $174.99.
| Scenario | MEDVi | Ivim Health | Difference |
|---|---|---|---|
| 1 month (try, then quit) | $179 | $149.99 (verify shorter-plan availability) | Ivim ~$29 cheaper |
| 3 months total cost | $179 + 2×$299 = $777 | Verify 3-mo plan availability and total at checkout | Likely Ivim cheaper if available |
| 6 months total cost | $179 + 5×$299 = $1,674 | $600 (6-mo medication) + 5×$74.99 = $974.95 | Ivim ~$700 cheaper |
| 12 months total cost | $179 + 11×$299 = $3,468 | $900 (12-mo medication) + 11×$74.99 = $1,724.89 | Ivim ~$1,743 cheaper |
| Quit at month 4 of a 6-mo plan | $179 + 3×$299 = $1,076 | ~$975 already prepaid + $50 admin fee per remaining 2-mo segment | Depends on quit timing |
The real tirzepatide math
| Scenario | MEDVi | Ivim Health | Approx. difference |
|---|---|---|---|
| 6 months total cost (compounded tirzepatide) | Verify current MEDVi tirz refill rate at checkout — recent reporting puts entry between $279–$349 with refills typically higher | $1,100 (6-mo med) + 5×$74.99 = $1,474.95 | Ivim is materially cheaper across all reported MEDVi tirz scenarios |
| 12 months total cost (compounded tirzepatide) | Verify current MEDVi tirz refill rate at checkout | $1,600 (12-mo med) + 11×$74.99 = $2,424.89 | Same — Ivim is materially cheaper |
If you want compounded tirzepatide and you're confident you'll commit, Ivim is the cheaper path. We say so even though we don't earn a commission from Ivim. That's how you know we mean it.
The two pricing gotchas to watch at checkout
MEDVi gotcha
The advertised entry price ($179) is a starting price, not the recurring price. If you go in expecting to pay $179/month forever, the second-month charge can feel like a bait. It's not — refill pricing is published — but you have to actually read it. Verify the refill rate at intake before you click “subscribe.”
Ivim gotcha
The “$75” on Ivim's pricing page is the medication-only price. The $74.99 program fee is on top, every month after the first month, and it's mandatory. Real total is roughly double the advertised number. Ivim discloses this, but it's possible to misread the pricing page on a quick scan.
Can you actually cancel? (The friction question that makes or breaks this)
The short answer: MEDVi is built for people who might want to quit. Ivim Health is built for people who already know they won't. MEDVi's published policy lets you cancel through your account with at least 72 hours' notice before your next billing date — no fees on the month-to-month plan. Ivim's prepaid plans cannot be cancelled mid-term without administrative fees of $50 per remaining 2-month segment or $100 per remaining 3-month segment of your plan.
MEDVi cancellation in plain English
- ✓Month-to-month plan: Submit cancellation through your account at least 72 hours before your next billing date. Miss the window, next charge processes, cancellation takes effect the cycle after.
- ✓Prepaid 3, 6, or 12-month plans: Refund terms are limited and vary — verify at checkout before prepaying. Month-to-month flexibility does not carry over.
- ✓Money-back terms: MEDVi advertises a "MEDVi Guarantee." Published refund policy specifies a full refund if the medical provider disqualifies you. Verify current results-based terms directly.
- ✓Medical disqualification: If a clinician determines GLP-1 isn't appropriate for you, MEDVi's policy permits a full refund.
Ivim Health cancellation in plain English
- !All medications are non-refundable: Once shipped — this is industry-standard for prescription meds. Both providers.
- !$74.99 program fee is non-refundable: Per Ivim's published Terms.
- !Prepaid plans cannot be cancelled mid-term without admin fees: $100 per undeveloped 3-month portion or $50 per undeveloped 2-month portion. A 6-month plan cancelled after 3 months triggers one $100 fee.
- !Fees are waived only if a provider determines medical ineligibility: e.g., pregnancy or a documented contraindication.
- !Renewal cancellation: Must cancel at least 48 hours before renewal to avoid the next cycle's charges.
What real complaints actually look like
Ivim most common complaint pattern
Charged for a multi-month plan before the prescription was confirmed, or difficulty getting refunds on prepaid plans. Billing timing, refund disputes, and shipping delays are the most frequent themes — resolved through direct outreach in most cases per their BBB profile.
MEDVi most common complaint pattern
Confusion at refill time — patients who didn't realize the refill rate was higher than the entry rate, or who tried to cancel within the same billing cycle and missed the 72-hour window. We have to be honest here: MEDVi's BBB profile currently shows an F rating, not accredited, with 368 complaints filed. Most are billing-related and resolved, but the volume is real. Trustpilot tells a different story (4.4/5, 12,500+ reviews, 78% 5-star), which is why both signals matter.
The flexibility verdict
If commitment risk is your concern, MEDVi is structurally the safer pick. You can start, see how your body responds, and walk away cleanly if it isn't right. With Ivim, the moment you select a 6 or 12-month plan, you've effectively committed to that timeline.
What medications and formats does each one offer?
The short answer: Both providers prescribe compounded semaglutide and compounded tirzepatide as weekly injections. MEDVi additionally offers daily oral tablet versions of compounded GLP-1 medications — useful if needles are a hard no for you. Both providers also offer FDA-approved brand-name medications, but with very different structures. A quick definition: compounded medications are prescription drugs prepared by licensed pharmacies based on an individual prescription. They are not FDA-approved as finished products and have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.
Compounded GLP-1 injections (both providers)
Both MEDVi and Ivim offer once-weekly subcutaneous injections of compounded semaglutide and compounded tirzepatide. Both use the standard titration protocol. GI side effects (nausea, constipation) are common during dose escalation; FDA has specifically warned about dosing errors with compounded injectable semaglutide and tirzepatide — verify dosing instructions, syringe markings, and concentration with your prescriber and pharmacy at every dose change.
Ivim's twist: GLP-1 ID protocol
Weekly check-ins through the Ivim app where a provider reviews your data and may adjust dose more frequently. Ivim has published an observational study (1,131 patients, Obesity Pillars journal) reporting 21.8% mean total body weight loss at 68 weeks — not a randomized controlled trial.
MEDVi's twist: operational simplicity
No app you must log into weekly. Your provider is available for messaging and dose adjustments, but the program runs on a “we'll talk if you need us” model rather than scheduled check-ins.
Oral tablet options — MEDVi only
MEDVi onlyMEDVi offers daily oral compounded GLP-1 tablets starting at $249 on their main program. Ivim does not currently offer oral compounded GLP-1s.
Real caveat on oral tirzepatide
In November 2025, a class-action lawsuit was filed against OpenLoop Health and compounding pharmacy Triad Rx alleging that compounded oral tirzepatide tablets cannot achieve therapeutic absorption. The named plaintiff allegedly purchased the tablets through MEDVi, though MEDVi was not named as a defendant per published reporting. This is allegation in pending litigation, not a proven finding. If you are considering oral tirzepatide from any provider, ask your prescriber about absorption and request a Certificate of Analysis on your batch.
Compounded oral semaglutide tablets are not FDA-approved and should not be presented as bioequivalent to FDA-approved Rybelsus or Wegovy. If you want oral semaglutide and FDA approval matters to you, Rybelsus is the FDA-approved oral semaglutide tablet for type 2 diabetes; off-label use for weight loss should be discussed with a prescriber.
Brand-name FDA-approved medications
MEDVi brand-name
Publicly advertises Wegovy Pill, Wegovy Injection, and Zepbound Injection at “$99 membership + medication cost.” Also lists Ozempic injection access at a higher cash-pay rate (verify current price at intake).
Ivim Health brand-name
Prescribes Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda when clinically appropriate, and submits prior-authorization paperwork to insurance. Best for readers who want concierge PA handling.
The bigger picture for FDA-approved + insurance
If FDA-approved brand-name with strong insurance support is your main need, Ro is currently the strongest path overall — broadest FDA-approved GLP-1 formulary (Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, Foundayo), matched pricing to LillyDirect / NovoCare / TrumpRx, dedicated insurance concierge that handles prior-authorization paperwork, and a free GLP-1 Insurance Coverage Checker. Get started for $39 first month, then as low as $74/month with annual prepay.
See our full Ro guide →What real customers actually say about each one
The short answer: Ivim Health holds a 4.9/5 on Trustpilot across roughly 36,700+ reviews — about 94% are 5-star, 2% are 1-star — and an A+ BBB rating, accredited since February 2023. MEDVi holds a 4.4/5 on Trustpilot across roughly 12,500+ reviews — about 78% are 5-star, 11% are 1-star — but its BBB profile shows an F rating, no accreditation, and 368 complaints. Reviews capture service experience, not clinical outcomes; both signals are useful but neither is the full picture.
| Signal | MEDVi | Ivim Health |
|---|---|---|
| Trustpilot rating | 4.4 / 5 | 4.9 / 5 |
| Trustpilot total reviews | ~12,500+ | ~36,700+ |
| Trustpilot 5-star share | ~78% | ~94% |
| Trustpilot 1-star share | ~11% | ~2% |
| BBB rating | F | A+ |
| BBB accredited? | No | Yes (since Feb 2023) |
| BBB complaints (3-year window) | 368 (failure to respond to 5) | Steady volume; resolved with direct outreach |
MEDVi positive patterns
Speed of approval, simplicity of the process.
MEDVi negative patterns
Refill price jumps, cancellation timing surprises (the 72-hour cutoff), and billing disputes. Pattern is more about expectations than the medication itself.
Ivim positive patterns
Individual provider names and weekly check-in quality.
Ivim negative patterns
Charged before clinical approval finalized, difficulty getting refunds on prepaid plans, occasional shipping delays, friction transitioning between support channels.
Public reviews are not a clinical safety database. They're a service-experience signal. Read them as such.
What the FDA warning letters actually said (and what they didn't say)
The short answer: Both MEDVi and Ivim Health received FDA warning letters dated February 20, 2026 — the same day, in the same FDA enforcement action that included 30 telehealth companies. Both letters cited misbranding — false or misleading marketing and labeling — not medication safety findings. Neither company has been ordered to stop operating. Both remain available to new patients.
MEDVi's FDA warning letter (Letter #721455)
The FDA sent MEDVi, LLC a warning letter on February 20, 2026, after reviewing MEDVi's website at the URL medvi.io in December 2025. The agency cited two issues:
- 1Product images displayed “MEDVi” on the medication label, which the FDA said suggested MEDVi compounds the drugs. MEDVi doesn't — it partners with external pharmacies.
- 2Marketing language including “Same active ingredient as Wegovy® and Ozempic®” which the FDA said implied FDA approval or evaluation of the compounded products.
medvi.io) was operated by an affiliate marketing agency, not directly by MEDVi. MEDVi's primary operating domain is medvi.org. MEDVi's CEO publicly stated on April 9, 2026 that MEDVi required the affiliate to remove the flagged materials. The letter did not allege contamination, mis-formulation, or unsafe medication. It addressed marketing.Ivim Health's FDA warning letter (Letter #721816)
The FDA sent Ivim Services LLC a warning letter on February 20, 2026 — same day — after reviewing Ivim's website in December 2025. The fundamental issue: Ivim's product imagery displayed “Ivim” on the medication label, suggesting Ivim is the compounder. Ivim isn't — it works with external 503A and 503B compounding pharmacies. Same enforcement wave. Same agency posture. Both letters used near-identical language because both companies (and 28 others in this category) had similar labeling and marketing patterns.
What this actually means for you
If you're a current patient at either provider and your medication is working
Nothing immediately changes. The FDA's letters were about how the providers describe their products, not about whether the medications themselves are safe. That said, FDA's broader position is that compounded GLP-1 drugs are not FDA-approved and have not been reviewed for safety, effectiveness, or quality before marketing. The absence of a safety finding in a misbranding letter is not a safety endorsement.
If you're a new patient evaluating either provider
This is real signal that the FDA is scrutinizing the compounded GLP-1 telehealth category harder than it was a year ago. The semaglutide and tirzepatide shortages that originally justified expanded compounding have eased; FDA has stated that semaglutide and tirzepatide do not currently appear on the FDA shortage list or 503B bulks list.
For your decision
Factor regulatory uncertainty into how much you pre-commit to either provider. A 12-month prepay is a heavier bet on continued compounded GLP-1 availability than a month-to-month plan. This is one more reason MEDVi's flexibility may matter to you.
Trust signals beyond the FDA letter
MEDVi
Active LegitScript certification on its website. Notes 500,000+ patients served. Counterpoint: BBB rates MEDVi F and not accredited, with 368 complaints.
Ivim Health
BBB A+ rating, accredited since February 28, 2023. Published observational research in Obesity Pillars. Counterpoint: Same billing and prepay-friction review patterns as subscription telehealth at scale.
Where can you actually get either of these? (State availability)
| Provider | State availability (verified) |
|---|---|
| Ivim Health | Publicly states 49 states plus Washington DC — Mississippi is the only excluded state |
| MEDVi | Serves the U.S. market broadly through its partner clinical network; state availability can vary by medication and program — verify your state at intake |
Check your state at intake before you put in payment information. Both providers will tell you up front if they can't serve your state.
Which pharmacies do MEDVi and Ivim Health use?
MEDVi — publicly named partner pharmacies
- ✓Triad Rx (Daphne, Alabama)
- ✓RedRock Pharmacy (St. George, Utah)
- ✓Beaker Pharmacy & Compounding (McKinney, Texas)
Per MEDVi's published Terms of Service. Note: Triad Rx is also named in the November 2025 oral-tirzepatide class action (pending litigation).
Ivim Health — pharmacy partners
Partners with both 503A and 503B compounding pharmacies but does not consistently name specific pharmacy partners on its public-facing pages.
If pharmacy disclosure is a decision factor for you, MEDVi has the cleaner public answer. If you want to know which specific pharmacy will fill your Ivim prescription, ask Ivim's support team directly before you enroll.
Are compounded GLP-1 medications safe? The bigger context
The short answer: The FDA says compounded drugs are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or manufacturing quality. That doesn't mean compounded medications are unsafe — millions of patients have used them through licensed pharmacies for decades — but it does mean the regulatory floor is lower than for FDA-approved brand-name products. The biggest safety lever you have as a patient is choosing a provider that uses a state-licensed pharmacy following USP standards, and asking for a Certificate of Analysis on your specific batch if anything looks off when it arrives.
The FDA reported 605 adverse events linked to compounded semaglutide and 545 linked to compounded tirzepatide as of July 31, 2025. These include dosing errors (often from drawing the wrong volume in a syringe — concentrations vary between brand-name and compounded products), contamination events, and allergic reactions to inactive ingredients not present in brand-name formulations.
The FDA has specifically warned about compounded products marketed as "semaglutide" that contain salt forms (semaglutide sodium, semaglutide acetate) — these are different compounds and are not covered by FDA's compounding exceptions. If you receive medication that doesn't list "semaglutide base" or simply "semaglutide" on the Certificate of Analysis, ask questions before using it.
GLP-1 medications carry a labeled contraindication for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). A history of pancreatitis is a clinical consideration that requires evaluation. Both MEDVi and Ivim screen for these in their intake — do not lie on intake forms.
This is not medical advice. If after reading this you're not comfortable with the regulatory profile of compounded medication, the FDA-approved brand-name path is real and worth considering — see the “Skip both if…” section below.
Pick MEDVi if…
The short answer: MEDVi is built for the buyer who wants flexibility, hates commitment, prefers oral tablets, wants brand-name FDA-approved medication on a cash-pay basis, or just isn't 100% sure GLP-1 will work for them. It is the simpler starting path. It costs more per month at standard rates than Ivim, but you can quit through your account dashboard with 72 hours' notice and you keep the option to walk away cleanly.
You should pick MEDVi if any of these describe you:
- ✓You want month-to-month flexibility — Cancel cleanly at any billing cycle with 72 hours' notice. No multi-month prepay required.
- ✓You're needle-averse — Oral compounded GLP-1 tablets start at $249 entry — MEDVi is the only major provider offering this.
- ✓You want FDA-approved Wegovy or Zepbound on a cash-pay basis — MEDVi advertises Wegovy Pill, Wegovy Injection, and Zepbound Injection at "$99 membership + medication cost."
- ✓You're not certain GLP-1 will work for you — A first-month MEDVi run is $179 in cash exposure. If your body doesn't respond well, you walk away with no continued obligation.
- ✓You want a provider that publicly names its compounding pharmacy partners — Triad Rx, RedRock Pharmacy, Beaker Pharmacy & Compounding — all three named in their Terms.
- ✓You want the simpler operational footprint — No app to log into weekly, no scheduled check-ins, support available when you need it.
Verify the final monthly price, refill rate, and cancellation terms at checkout before paying.
Pick Ivim Health if…
The short answer: Ivim is built for the buyer who already knows they're committing, wants the lowest total cost on compounded medication, wants weekly precision-dosing check-ins, and can absorb the cancellation administrative fees if they change their mind. We don't have an affiliate link to them, and we say that anyway.
You should pick Ivim Health if any of these describe you:
- ★You're confident you'll stay on a GLP-1 program for at least 6–12 months — The full economic case for Ivim assumes you actually complete the plan you commit to.
- ★You want the lowest total cost — $1,724.89 for 12 months of compounded semaglutide vs. MEDVi's $3,468 isn't close.
- ★You want a published peer-reviewed observational study — Ivim's Obesity Pillars paper documented 21.8% mean total body weight loss at 68 weeks across 1,131 patients — not a randomized controlled trial.
- ★You want weekly precision-dosing check-ins — Ivim’s GLP-1 ID protocol with weekly app-based provider review.
- ★You want brand-name Wegovy, Zepbound, Ozempic, Mounjaro, or Saxenda with insurance prior-authorization help — Ivim handles the prior-auth paperwork.
- ★You want HSA/FSA payment with Klarna pay-over-time financing — Available at checkout.
- ★You want a BBB-accredited provider — A+ rating since Feb 2023.
Skip both if…
The short answer: Neither MEDVi nor Ivim is the right first click if you specifically want FDA-approved brand-name medication with strong insurance support, if compounded medication makes you uncomfortable, or if you have a contraindication. Both are compounded-first platforms. If your real need is something else, you deserve the right page.
You should skip both providers if:
You want FDA-approved brand-name Wegovy, Zepbound, or Foundayo with insurance prior-authorization support
Ro is currently the strongest path — broadest brand-name formulary, matched pricing to LillyDirect / NovoCare / TrumpRx, dedicated insurance concierge, and a free GLP-1 Insurance Coverage Checker. Get started for $39 first month, then as low as $74/month with annual prepay.
Get started with Ro: $39 first month →You're not comfortable with compounded medication's regulatory uncertainty
That's a legitimate position. Brand-name FDA-approved GLP-1s skip the compounding question entirely.
You have Medicare or Medicaid and want coverage clarity
Neither MEDVi nor Ivim is built around Medicare/Medicaid; this needs a different conversation.
You're pregnant, trying to become pregnant, or breastfeeding
GLP-1s are not appropriate during pregnancy. Talk to your OB before any GLP-1 decision.
You have a personal or family history of medullary thyroid carcinoma (MTC) or MEN-2
These are documented contraindications. GLP-1 isn't your medication.
You're absolute-cheapest shopping and willing to use a smaller, async-only provider
See our cheapest GLP-1 providers guide for the value-tier options.
See our cheapest GLP-1 providers guide →
The one thing nobody warns you about with either provider
The shared blind spot
Neither MEDVi nor Ivim Health offers strong long-term clinical follow-up for what happens after you stop the medication. Both programs are built around getting you on GLP-1, getting you to your goal weight, and managing the months you're on the drug. Neither has a published, structured maintenance protocol for the year after you discontinue.
Published research on GLP-1 medications, including the STEP 4 trial, shows that patients who discontinue semaglutide regain a significant portion of lost weight over time compared to patients who continue. The providers don't prominently address the transition-off plan, the behavioral changes that reduce regain risk, or the clinical evidence on maintenance dosing. If long-term weight management is your goal, ask either provider what their post-discontinuation plan looks like before you sign up.
Update cadence: This page is re-verified quarterly minimum. Sooner if a material change occurs (pricing change, regulatory action, new FDA enforcement). Last verified .
MEDVi vs Ivim Health: frequently asked questions
Is MEDVi cheaper than Ivim Health?▼
Does Ivim Health have a membership fee?▼
Does MEDVi have a membership fee?▼
Can you cancel MEDVi anytime?▼
Can you cancel Ivim Health mid-plan?▼
Are MEDVi and Ivim Health legit?▼
Which one offers oral tablets?▼
Does MEDVi or Ivim Health accept insurance?▼
Which one has better customer reviews?▼
What did the FDA warning letters say about MEDVi and Ivim Health?▼
Can I switch from another GLP-1 provider to MEDVi or Ivim?▼
Still not sure which GLP-1 program is right for you?
Your situation is more specific than this page. The right provider depends on your state, your insurance situation, your formulation preference, your budget and commitment tolerance, and your comfort with compounded medication. Sometimes the answer is neither MEDVi nor Ivim.
Take our 60-second matching quiz
Routes you to the best-fit GLP-1 provider for your specific situation across 25+ verified telehealth platforms — not just MEDVi and Ivim.
Take the 60-second matching quiz →Already decided on MEDVi?
Month-to-month plan, $179 entry for compounded GLP-1 injections. Verify your state and the refill rate before paying.
Start with MEDVi (month-to-month, $179 entry) →About this page
Author: Weight Loss Provider Guide editorial team
· · Update cadence: Quarterly minimum
Primary sources verified: MEDVi GLP-1 program page (glp.medvi.org) and Refund Policy; Ivim Health pricing page and Subscription Agreement; FDA Warning Letter #721455 to MEDVi, LLC and #721816 to Ivim Services LLC, both February 20, 2026 (FDA.gov); both BBB profiles; both Trustpilot profiles accessed April 28, 2026; FDA's “Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” guidance.
Affiliate disclosure: This page contains affiliate links to MEDVi. If you sign up through our link, we may earn a commission at no extra cost to you. We have no commercial relationship with Ivim Health. Our recommendations are based on verified pricing and policies, not commission rates.
Related guides on Weight Loss Provider Guide
This page is informational and is not medical advice. GLP-1 medications require evaluation by a licensed clinician. Talk to your prescriber before starting, switching, or stopping any GLP-1 medication. Compounded medications are not FDA-approved as finished products and have not been reviewed by the FDA for safety, effectiveness, or quality before marketing. Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not a medical provider, do not write prescriptions, and do not provide medical advice.